RankingsPricing
  1. US-listed companies
  2. LIGAND PHARMACEUTICALS INC
  3. Financials
  4. Capital expenditures

LIGAND PHARMACEUTICALS INC【LGND】

Market cap
$4B
P/E ratio
SummaryFinancials
Period EndCapital expenditures (Million USD)YoY (%)
Dec 31, 2024-2-48.28%
Dec 31, 2023-4-80.35%
Dec 31, 2022-18+104.58%
Dec 31, 2021-9+96.52%
Dec 31, 2020-4+74.62%
Dec 31, 2019-3+187.82%
Dec 31, 2018-1-58.86%
Dec 31, 2017-2+16.54%
Dec 31, 2016-2+1889.25%
Dec 31, 2015-0+1450.00%
Dec 31, 2014-0-98.41%
Dec 31, 2013-0-36.64%
Dec 31, 2012-1+662.82%
Dec 31, 2011-0

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)